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Abstract
Background: Treatment of cryptosporidiosis in HIV infected children has proved difficult and
unsatisfactory with no drugs having demonstrable efficacy in controlled trials except nitazoxanide.
We hypothesised that a prolonged course of treatment with high dose nitazoxanide would be
effective in treating cryptosporidiosis in HIV positive Zambian children.
Methods:  We performed a double-blind, randomised, placebo controlled trial in paediatric
patients in the UTH in Lusaka. The study included HIV positive children between one and eleven
years of age if 2 out of 3 stool samples were positive for oocysts of Cryptosporidium spp. Children
were given nitazoxanide suspension in a dose of 200 mg twice daily (bid) for 28 days (if 1-3 years
old) or 400 mg bid for 28 days (if 4-11 years old), or matching placebo.
Results: Sixty children were randomised and 52 were fully evaluated. Only five children were 4
years of age or over and received the higher dose. In the primary efficacy analysis, 11 out of 26
(42%) in the active treatment group achieved a 'Well' clinical response compared to 8 out of 26
(35%) in the placebo group. Parasitological response was declared as 'Eradicated' in 27% in the
active group and 35% in the placebo group. Mortality (16/52, 31%) did not differ by treatment
allocation.
Conclusion: We found no significant benefit in children with cryptosporidiosis despite high dose
and longer treatment duration. This is the second randomised controlled trial to suggest that in
Zambian children with HIV-related immunosuppression nitazoxanide does not eradicate this
infection nor provide clinical symptom reduction.
Trial Registration: The trial was registered as ISRCTN41089957.
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Background
Cryptosporidiosis is an important cause of morbidity and
mortality in malnourished children [1,2] and in children
with AIDS [2]. In immunocompetent children crypt-
osporidiosis is a frequent cause of diarrhoea [3], and even
these episodes which are usually of limited duration can
have long-term consequences [4]. However, treatment
remains difficult and unsatisfactory, with no drugs having
any proven efficacy except nitazoxanide [5-7]. We have
previously reported that three day treatment with the anti-
parasitic drug nitazoxanide was effective in treatment of
HIV-seronegative children but demonstrated insignificant
activity in HIV-seropositive children [8]. There is an
urgent need for effective treatment for cryptosporidiosis in
HIV-infected children [9]. We postulated that the per-
formance of this drug in such patients could be improved
by a higher dosage and by giving a longer course of treat-
ment. We report here the results of a randomised control-
led trial to evaluate this hypothesis in the same setting as
our earlier study. The doses of nitazoxanide chosen were
double those used in the previous study, and the duration
was increased from 3 to 14 days. Ethics approval was
obtained from the University of Zambia Research Ethics
Committee. The trial was registered as ISRCTN41089957.
Methods
We carried out a double-blind, randomised, placebo con-
trolled trial in paediatric patients shown to be positive for
both HIV and cryptosporidiosis, in the children's diar-
rhoea/malnutrition ward of the University Teaching Hos-
pital, Lusaka. Children were included if between 1 and 11
years of age, if positive in at least 2 of 3 stool samples for
Cryptosporidium spp. (oocysts identified using auramine
phenol staining), if they had had diarrhoea with 3 or
more unformed stools daily, and if HIV seropositive as
confirmed by the Capillus Rapid Test (Trinity Biotech, Ire-
land). If Cryptosporidium spp. oocysts were present in the
initial screening but not in the baseline samples, the
patient was excluded unless they tested positive for
oocysts within one week from this first sample. Children
were excluded if they had a bacterial cause for diarrhoea
or if positive for Entamoeba histolytica or Giardia lamblia by
the Triage® Parasitic Panel (Biosite Diagnostics, San Diego,
CA). Other exclusion criteria were a history of investiga-
tional drug therapy within one month prior to enrolment,
or other recognised anti-protozoal therapy within two
weeks prior to enrolment. Children who were moribund
were not randomised and gravely ill were observed for a
period of 1-2 weeks prior to randomisation.
Study procedures
At the initial visit a complete medical history was
reviewed to evaluate conformity with inclusion and exclu-
sion criteria. A physical examination was conducted
including body weight, height and mid-upper arm cir-
cumference. Clinical symptoms and a subjective assess-
ment of stool features (consistency, frequency, presence of
blood of mucus) were recorded. Blood tests were carried
out including complete blood count, alanine aminotrans-
ferase, aspartate aminotransferase, γ-glutamyl transferase,
alkaline phosphatase, creatinine, random blood glucose,
electrolytes (Na and K) and a CD4 count. Urinalysis was
also carried out. Blood and urine tests were also per-
formed at week 2 (day 15) and the end of the treatment,
and the physical examination was repeated on days 8, 15,
22 and the end of the study (day 28). Case report forms
were used to record any adverse affects of the drug.
Randomisation and masking of treatment allocation
Eligible candidates were randomly assigned a sequential
patient number; using this number a medication pack of
either placebo or nitazoxanide was dispensed. This corre-
sponded to a computer-generated random number list
generated by the study sponsor, the Romark Institute for
Medical Research, Tampa, Florida, USA. The randomisa-
tion code was generated in blocks of 10 so that active and
placebo groups balanced in each sequential group of 10.
Children were given nitazoxanide suspension in a dose of
200 mg twice daily (bid) for 28 days (if 1-3 years old) or
400 mg bid for 28 days (if 4-11 years old), or matching
placebo. This represents an average dose of 54 mg/kg/day.
Only five children received the higher dose. The dose was
administered as 10 ml of a suspension containing 20 mg/
ml nitazoxanide or placebo (for younger children), and
20 ml of this suspension for the older children. Both nita-
zoxanide and placebo were administered in powder form
and reconstituted into a strawberry flavoured paediatric
suspension every morning and evening; nitaxozanide and
placebo suspensions were identical in appearance, odour
and taste. Recruitment decisions were made by the study
physician (BA) and nurse leader (AW) and treatment allo-
cation initiated by them using the numbered containers.
The nitazoxanide was supplied by Romark Laboratories in
containers identifiable only by a code on the label, the key
to which was held by Romark Laboratories until the end
of the trial so that the trial was fully double-blind. All par-
ticipants of the trial remained in hospital for the duration
of the treatment and had access to intravenous fluids,
antibiotics, oral rehydration therapy and micronutrients
(including zinc and vitamin A). Nutritional support in the
form of skimmed milk based feed was provided through-
out the study.
A provision was made for the supply of open label treat-
ment with nitazoxanide for patients experiencing clinical
deterioration throughout the trial or in the event of non-
response after the initial treatment phase of the study.
This was to reduce the possible disadvantages of being in
the placebo group. If patients initially responded to treat-
ment but relapsed or were re-infected during the 60 daysBMC Infectious Diseases 2009, 9:195 http://www.biomedcentral.com/1471-2334/9/195
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following treatment open label treatment was also availa-
ble. This was also an option to children excluded from the
trial. Patients receiving open label treatment were moni-
tored regularly and blood, urine and faecal samples were
analysed using trial protocols.
Clinical and parasitological endpoints
While in hospital study subjects were administered test
medication daily every 12 hours and clinical symptoms
and any possible adverse effects were assessed and docu-
mented daily. Clinical response was recorded as 'Well' if
there were no symptoms of Cryptosporidium spp. infection
and no watery stools in the 48 hours leading up to the
final dose of nitazoxanide. If there was clinical deteriora-
tion or worsening symptoms after at least 24 hours of
treatment the subject was considered to show 'Clinical
Treatment Failure' and open-label rescue therapy would
be implemented. The status of 'Continuing Illness' was
used to classify patients without a 'Well' or 'Clinical Treat-
ment Failure' response. Stool samples were examined
every Monday, Wednesday and Friday until two consecu-
tive samples were judged to be clear. Auramine phenol
staining technique was used to identify Cryptosporidium
spp. oocysts in concentrated and unconcentrated stools.
Parasitologic response was either identified as 'Eradica-
tion' when no oocysts of Cryptosporidium  spp. were
observed in two consecutive stool samples or 'Persistence'
for any outcome other than 'Eradication'. Clinical
responses were declared after joint consultation by the
study team physician (BA) and lead nurse (AW) and the
parasitological response was declared by the team parasi-
tologist (SS).
Data analysis
A modified intent-to-treat population was used for the
primary efficacy analysis, as specified in the protocol. This
population included all patients randomised excluding
(1) patients who did not receive any study medication, (2)
patients with no oocysts in the baseline stool sample if
Cryptosporidium infection was not confirmed by one of the
two stool examinations within one week of baseline, and
(3) patients with bacterial causes of diarrhoea identified
by stool culture. The primary endpoints were the propor-
tion of children achieving a well clinical response and
time to a well clinical response. Secondary endpoints
were: eradication of Cryptosporidium  spp. oocysts from
stool and time to eradication, a combination of time to
eradication of oocysts and well clinical response, and
mortality rates. A further secondary endpoint was the rate
of improvement in diarrhoea frequency during treatment
as determined by subject-specific regression modelling
[10].
Time to well clinical response was calculated from the
interval between the date of first administration of nita-
zoxanide and the date of 'Well' clinical response recorded
by physician. The time to eradication of oocysts from
stool was calculated from the interval between the date of
first administration of nitazoxanide and the date of the
first consecutive negative examination for oocysts. For the
secondary endpoint of clinical response and eradication,
this is regarded for each patient as the longer of the two
from either time to eradication of oocyst or time to clini-
cal response. Adverse events were coded in accordance
with the COSTART dictionary and proportions of patients
experiencing these affects were compared with Fisher's
exact test. Laboratory tests were compared by treatment
group using analysis of variance tests for comparing
means and chi-square tests to compare proportions. Sta-
tistical analysis was carried out using Stata 10 (Stata Corp,
College Station, Texas).
The sample size was calculated from previous experience
where there was 80% clinical response rate for the active
treatment group and a 35% response rate for the placebo
treatment group after two weeks of treatment. Sixty chil-
dren who were both HIV seropositive and tested positive
for Cryptosporidium spp. were included in the trial. With a
sample size in each group of 25 the trial was predicted to
have 80% power with 95% confidence to detect the differ-
ence sought between the two groups. There was no provi-
sion for an interim analysis or for stopping the trial.
Results
Of 409 children with cryptosporidiosis identified during
the duration of the trial, 130 did not meet the entry crite-
ria, 122 declined (mostly due to reluctance of the family
to consent to hospitalisation for the period of the study),
129 seriously ill children died during the period of obser-
vation and 28 withdrew before randomisation (Figure 1).
Sixty HIV seropositive children with cryptosporidiosis
were randomised during the period of the trial which was
from October 2002 to June 2004. Eight subjects (four
from each treatment group) were excluded from the mod-
ified intent-to-treat population because they were not still
passing oocysts at baseline (n = 4) or because stool culture
identified bacterial causes of diarrhoea (n = 5). One sub-
ject was excluded for both of these reasons. The demo-
graphic characteristics of the children enrolled are shown
in Table 1.
Primary endpoints
The primary efficacy analysis (Table 2) showed 11 out of
26 subjects (42%) in the active treatment group showed a
'Well' clinical response compared to 8 out of 26 (31%) in
the placebo group (P  = 0.39). In an intention-to-treat
analysis, time to 'Well' clinical response was (mean, SD)
12.2 (9.6) days in the NTZ group and 13.8 (9.7) days in
the placebo group (P = 0.52 using t test). These figuresBMC Infectious Diseases 2009, 9:195 http://www.biomedcentral.com/1471-2334/9/195
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were also compared using a log-rank test and no signifi-
cant difference was observed (P = 0.37).
Secondary endpoints
Parasitological response (Table 2) was declared as 'Eradi-
cated' in 7 out of 26 subjects (27%) in the active group
compared to 9 out of 26 (35%) in the placebo group (P =
0.55). Time to 'Eradicated' parasitological response was
(mean, SD) 15.3 (11.3) days in the NTZ group and 16.1
(10.6) days in the placebo group (P = 0.79 using t test).
These figures were also compared using a log-rank test and
no significant difference was observed (P = 0.65). Com-
bined clinical and parasitological response was observed
in 5 out of 26 (19%) in the nitazoxanide group showed
the combination of these features compared with 4 out of
26 (15%) in the placebo group (P = 0.71 using t test).
There was no significant difference in the time for these
features between the two test groups (P = 0.68 by the log-
rank test). When trends in diarrhoea frequency were com-
pared using subject-specific regression modelling, no dif-
ference was found in the regression (β-) coefficients
between the two groups (P = 0.55).
Mortality
Ten out of twenty six patients (38%) in the active treat-
ment group died during the course of the study compared
to six out of twenty six patients (23%) in the placebo treat-
ment group (P = 0.23 by χ2 test) although there was no
significant difference in terms of survival time by treat-
ment group (P = 0.34, log-rank test).
Adverse Events
56 adverse events were recorded in 21 different patients,
13 of these were in the nitazoxanide group and 8 were in
the placebo. Of these events, 52 were considered to be
serious although all of these were related to the patients'
HIV-related illnesses and were considered to be not
related to the treatment. Two events were considered to be
possibly related to the treatment and these were one case
of moderate vomiting, and a case of mild discoloration of
the sclera (liver function tests normal) both observed in
the nitazoxanide treatment group. The proportions of
patients reporting adverse events were compared by group
and there were no significant differences in the frequency
or nature of adverse events reported in the two treatment
groups.
Flow of participants through the trial Figure 1
Flow of participants through the trial.
Children with persistent diarrhoea
n=1546
Cryptosporidiosis confirmed
n=409
Negative samples 
n=1137
Randomised to NTZ
n=30
Dropped out:
Withdrew n=28, DNMEC n=130, 
Declined n=122, Death n=129
Evaluated after treatment with NTZ
n=26
Randomised to NTZ but dropped from 
modified ITT analysis n=4
Randomised to placebo
n=30
Evaluated after treatment with placebo
n=26
Randomised to placebo but dropped from 
modified ITT analysis n=4BMC Infectious Diseases 2009, 9:195 http://www.biomedcentral.com/1471-2334/9/195
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Discussion
Cryptosporidiosis is a serious infection which carries
increased mortality in children in tropical countries. The
severity of this mortality problem is evident from the
deaths in this trial despite attentive medical and nursing
care, and this underscores the need for more effective
treatments. In a previous randomised, double-blind, pla-
cebo controlled trial, nitazoxanide was an effective treat-
ment for HIV negative children with infection with
Cryptosporidium spp. and even at a lower dosage resulted
in resolution of the diarrhoea in only three days [8]. In
that trial we were unable to demonstrate any significant
benefit from the use of higher dose and prolonged treat-
ment with nitazoxanide in HIV positive patients with
cryptosporidiosis. In the current study we were again not
able to demonstrate any effect of nitazoxanide in this
group of patients, even at higher dose. The situation
remains that in immunocompromised patients there is
still no effective treatment for this important infection
[6,7,9] even though non-randomised evidence suggests
that in individual cases there may sometimes be a
response [11].
It appears that in the face of HIV-related immunosuppres-
sion even a powerful antiprotozoal agent such as nitazox-
anide [12,13] cannot eradicate Cryptosporidium spp. The
precise mechanism of this attenuation of anti-parasitic
drug effect is not clear but it would be expected to be
related to a decline in population of CD4 (probably Th1-
mediated) cells in the gut [14-16]. It is also possible that
it could be a specific relative deficiency of interferon-γ. It
would be interesting to compare children with varying
degrees and causes of immunosuppression who also have
cryptosporidiosis to identify the particular mechanism of
evasion employed by the protozoa during persistent infec-
tion. There could also be an effect of varying parasitic load
among trial candidates. It has long been suspected that
different individuals suffer from different degrees of para-
Table 1: Baseline characteristics of trial participants
Intention-to-treat (ITT) analysis Modified ITT analysis
NTZ Placebo NTZ Placebo
Number of children 30 30 26 26
Sex (M:F) 14:16 20:10 13:13 18:8
Age (months) 20 (11.3) 21 (20.2) 21 (11.9) 22 (17.8)
CD4 count (cells/μL) 579 (378) 614 (403) 583 (316) 503 (394)
Weight (kg) (mean, SD) 7.2 (1.8) 7.3 (2.0) 7.3 (2.0) 7.3 (2.0)
Presence of oedema (number, %) 6 (20) 5 (17) 5(19) 4 (15)
Hb (g/dL) (mean, SD)
[range]
8.7 (2.2)
[4.9-12.8]
8.3 (1.8)
[4.5-13.1]
8.3 (1.8)
[5.8-11.9]
8.2 (2.0)
[4.5-13.1]
WBC (×109/L) 11.6 (6.2)
[4.7-35]
11.0 (5.1)
[3.2-21.9]
12.5 (6.7)
[5.2-35]
10.9 (5.1)
[4.7-13.1]
Na+ (mmol/L) 137.2 (2.5) 137.6 (1.9) 137.3 (3.3) 138.3 (1.0)
K+ (mmol/L) 4.4 (0.5) 4.4 (0.5) 4.5 (0.6) 4.5 (0.5)
Creatinine (μmol/L) 95.5 (39.2) 89.1 (38.3) 95.6 (34.8) 92.4 (38.2)
Alkaline phosphatase (i.u./l) 148 (72) 164 (69) 151 (77) 168 (61)
AST (i.u./l) 62.1 (61) 61 (22) 54 (23) 64 (22)
ALT (i.u./l) 45 (30) 48 (25) 45 (30) 48 (26)
Values shown are mean (SD) unless otherwise specified; where shown, values in square brackets represent range. Statistical testing using the t test 
or Fisher's exact test showed no significant differences between NTZ and placebo groups by either ITT or PP analysis.BMC Infectious Diseases 2009, 9:195 http://www.biomedcentral.com/1471-2334/9/195
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sitaemia due to innate, possibly genetic, factors and it may
be that both recovery from diarrhoea and drug efficacy
depend on the initial load of parasites present. It is also
evident that any further trials of nitazoxanide would ben-
efit by greater understanding of the mechanisms involved
in suppression of Cryptosporidium spp. and hopes for treat-
ment of this protozoan pathogen would be enhanced by
an improved understanding of the immune responses
that can clear it in immunocompetent individuals.
This study was designed to outline any possible benefit of
treating children suffering from AIDS related crypt-
osporidiosis with an increased dosage of nitazoxanide.
Previous trials had used lower dosages and a limited treat-
ment period showing no substantial improvement. The
sample size was set to detect only a large effect of nitazox-
anide as we believe that only large treatment effects are of
real interest in a very vulnerable group of patients, such as
this, in a resource-poor setting. This may reduce the power
of the study. Our results show no significant benefit in
this increased dosage and longer course of treatment for
these patients. Although it has been previously shown in
adults with AIDS related cryptosporidiosis that nitazoxa-
nide can improve to a modest extent the clearance of the
parasite and reduce the period of clinical symptoms [10],
we saw no such effect here. As anticipated in this group of
children [2], mortality was high (28% within 28 days).
This may have reduced the power of the study to detect
efficacy as only 18 in the nitazoxanide group and 19 in the
placebo group actually completed the course of treatment.
We carried out a modified intention-to-treat analysis as
the trial protocol specified that children without oocysts
at randomisation would be excluded from the analysis, as
would children with bacterial causes of diarrhoea. Never-
theless, there was little suggestion of efficacy against any
of several endpoints no matter what sort of analysis was
conducted.
Conclusion
At this dose and duration of treatment, nitazoxanide can-
not be recommended for HIV-related cryptosporidiosis in
Zambian children.
List of Abbreviations
HIV: human immunodeficiency virus; UTH: University
Teaching Hospital, CD4: cluster differentiation antigen 4.
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Table 2: Clinical and parasitological responses
Intention-to-treat analysis Modified ITT analysis
NTZ Placebo NTZ Placebo
Number of children 30 30 26 26
Primary endpoints
Proportion achieving well clinical response (number, %) 14 (47) 12 (40) 11 (42) 8 (31)
Time to well clinical response(days) 11.4 (7.2) 7.9 (4.8) 12.2 (9.6) 13.8 (9.7)
Secondary endpoints
Parasitological eradication (number, %) 10 (33) 12 (40) 7 (27) 9 (35)
Time to parasite eradication (days) 8.7 (7.0) 11.7 (9.0) 8.0 (6.3) 13.8 (9.5)
Time to combined clinical and parasitological response 19.1 (11.5) 20.3 (10.1) 12.7 (8.4) 14.2 (7.8)
Mortality (deaths by 4 weeks) 11 (37) 6 (20) 10 (38) 6 (23)
Rate of reduction in stool frequency (expressed as change per day during treatment) 
(mean, SD)
-0.21 (0.34) -0.16 (0.25) - -
Nutritional response (change in weight over 4 weeks, kg) (mean, SD) 0.8 (1.0) 1.2 (0.9) 1.3 (0.8) 1.6 (0.8)
- not analysed; ITT, intention-to-treat. Rate of change in diarrhoea frequency was only analysed on a strict ITT basis. Statistical testing using the t 
test or Fisher's exact test showed no significant differences between NTZ and placebo groups.Publish with BioMed Central    and   every 
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